Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Early Phase 1
1(33.3%)
3Total
N/A(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07070921Not ApplicableRecruiting

Assessing Safety and Performance of the Novel CytaCoat Foley Catheter

Role: lead

NCT06242600Early Phase 1Completed

Evaluation of Safety and Performance of the CytaCoat Lubricious Infection Prevention (LIP) Foley Catheter

Role: lead

NCT02756351Not ApplicableCompleted

A Efficacy and Safety Study of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization

Role: lead

All 3 trials loaded